# Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

> **NCT00996658** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 278 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** Linagliptin

## Key facts

- **NCT ID:** NCT00996658
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2014-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996658, "Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00996658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*